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Abstract
Background: Immunological dysfunctions in the course of depres-
sion are recently intensively investigated. Pharmacotherapy of de-
pression is speculated to affect immune response. In this study, our 
objective was to investigate whether escitalopram treatment would 
affect white blood cells in patients with major depression.
Methods:  Fifteen patients (11 women and 4 men), meeting the 
criteria for a current episode of major depressive disorder, were par-
ticipated. White blood cell (WBC), neutrophil (NEUT), lympho-
cyte (LYMPH), monocyte (MONO), eosinophyl (EO), and baso-
phyl (BASO) levels were measured at the entry to the study. After 8 
weeks of open-label treatment with the selective serotonin reuptake 
inhibitor escitalopram (10-20 mg/d), the patients were readmitted 
and the measurements were repeated.
Results: At the end of the study, LYMPH was found to be signifi-
cantly decreased compared to the baseline value after 8 weeks treat-
ment with escitalopram (p < 0.001). There was not a significant 
change in WBC, NEUT, MONO, EO, and BASO parameters. 
Conclusions:  The present study has shown that escitalopram in-
creased LYMPH in patients with major depression according to 
these results, the possible treatment of depression with escitalo-
pram must be carried out with caution, in patients with immuno-
logical disturbances.
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Introduction
Immunological dysfunctions in the course of depression are 
recently intensively investigated, but the results are inconsis-
tent, possibly due to etiological variability of depression [1]. 
Both immunosuppression and pathological activation, simi-
lar to that observed in inflammation or autoimmune diseases, 
were reported [1, 2]. It has been demonstrated that pharma-
cotherapy  of  depression  results  in  normalization  of  some 
disturbed indices of immunoreactivity [2]. In this study, our 
objective was to investigate whether escitalopram treatment 
would affect white blood cells in patients with major depres-
sion.
 
Patients and Methods
The study was conducted in an outpatient clinic from April 
2008 through August 2008. Fifteen patients (11 women and 
4 men), meeting the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) criteria for a cur-
rent episode of major depressive disorder (MDD) (age, mean 
± SD, 37 ± 10 years) were recruited. The eligible patients 
were physically healthy, aged 18 years or older. All of them 
had a baseline Montgomery-Asberg Depression Rating Scale 
(MADRS) [3] total score of at least 22. White blood cell 
(WBC), neutrophil (NEUT), lymphocyte (LYMPH), mono-
cyte (MONO), eosinophyl (EO), and basophyl (BASO) lev-
els were measured at the entry to the study. Blood samples 
were drawn after a fasting period of 12 h. They were obtained 
on the morning before starting the first dose of escitalopram. 
After 8 weeks of open-label treatment with the selective se-
rotonin reuptake inhibitor escitalopram (10-20 mg/d), the 
patients with depression were readmitted and the measure-
ments were repeated. All the patients were newly diagnosed 
and were not treated for depression previously. Written, in-
formed consent was obtained, and the Ethics Commitee of 
Duzce University, Medical School Local Ethical Commitee 
for Clinical and Laboratory Studies, Turkey approved the 
study protocol. The study was conducted in accordance with 
the Declaration of Helsinki. Statistical analysis was done 
by SSPS statistical software (SPSS for windows 15.0, Inc., 
Chicago, IL, USA). Data were tested for normal distribution 
using the Kolmogorov–Smirnov test. Paired t-test was used 
to determine whether there was a significant difference be-
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tween basal and posttreatment variables. Data are expressed 
as mean ± standart deviation. Statistical significance was de-
fined as p < 0.05.
 
Results
At the end of the study, LYMPH was found to be significant-
ly decreased compared to the baseline value after 8 weeks 
treatment with escitalopram (p < 0.001). There was not a 
significant change in WBC, NEUT, MONO, EO, and BASO 
parameters (Table 1).
Discussion
  
Numerous observations indicate that the changes in the state 
of the central nervous system, particularly of the mood lev-
el, are accompanied by the changes in immunological sta-
tus of the organism, and conversely, the diseases involving 
immunological responses influence behavior [4]. Serotonin 
was found to modulate immunological responses such as 
proliferation  of  lymphocytes  induced  by  mitogens  [5,  6]. 
Serotonin in lymphatic organs derives from macrophages, 
lymphocytes, basophils, mast cells and blood platelets, and 
also, secondarily, the noradrenergic sympathetic nerve end-
ings, that are capable of serotonin reuptake [7]. Available 
data demonstrate that serotonin affects the immunological 
responses both in vitro and in vivo conditions, and its action 
is biphasic: low concentrations of serotonin stimulate, while 
its high levels suppress the immunological system. Thus, 
serotonin may be regarded as an autocrine and paracrine 
modulator of immunological responses [5, 6]. 
The present study has shown that escitalopram increased 
LYMPH in patients with major depression. This study in-
dicates that the escitalopram, a selective serotonon reuptike 
inhibitor antidepressant, seems to have a lymphocyte prolif-
erative effect. According to these results, the possible treat-
ment of depression with escitalopram must be carried out 
with caution, in patients with immunological disturbances.
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Before treatment After treatment p value
WBC 6.93 ± 2.43 6.78 ±1.35 0.732
NEUT 4.46 ± 2.05 3.97 ± 0.94 0.218
LYMPH 1.82 ± 0.55 2.08 ± 0.49 0.008
MONO 0.57 ± 0.20 1.61 ± 0.68 0.167
EO 0.20 ± 0.41 0.30 ± 0.66 0.644
BASO 0.19 ± 0.01 0.20 ± 0.01 0.751
Table 1. Baseline And Post Escitalopram Treatment Values of White Blood Cells
White Blood Cell (WBC), neutrophil (NEUT), lymphocyte (LYMPH), monocyte (MONO), eosinophyl 
(EO), and basophyl (BASO).
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